keyboard_arrow_up

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Therapeutics Assessment Pipeline Review, H1 2014

RnRMarketResearch.com adds “Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections – Pipeline Review, H1 2014” to its store. The report provides an overview of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Complete report available @ http://www.rnrmarketresearch.com/methicillin-susceptible-staphylococcus-aureus-mssa-infections-pipeline-review-h1-2014-market-report.html .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections; The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities; The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects; The report summarizes all the dormant and discontinued pipeline projects; A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources; Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages; A detailed assessment of monotherapy and combination therapy pipeline projects; Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type; Latest news and deals relating related to pipeline products.

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies; Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage; Develop strategic initiatives by understanding the focus areas of leading companies; Identify and understand important and diverse types of therapeutics under development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections; Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline; Devise corrective measures for pipeline projects by understanding Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline depth and focus of Indication therapeutics; Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope; Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables

Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, H1 2014 8
Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by Dainippon Sumitomo Pharma Co., Ltd., H1 2014 17
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by Immtech Pharmaceuticals, Inc., H1 2014 18
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by Cellceutix Corporation, H1 2014 19
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by Lytix Biopharma AS, H1 2014 20
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by PharmaIN Corporation, H1 2014 21
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by ImmuVen, Inc., H1 2014 22
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline by Arsanis Biosciences GmbH, H1 2014 23
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 30
Number of Products by Stage and Route of Administration, H1 2014 32
Number of Products by Stage and Molecule Type, H1 2014 34
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections Therapeutics - Recent Pipeline Updates, H1 2014 48
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Dormant Projects, H1 2014 56
Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Discontinued Products, H1 2014 57

List of Figures

Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, H1 2014 8
Number of Products under Development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 24
Number of Products by Top 10 Target, H1 2014 25
Number of Products by Stage and Top 10 Target, H1 2014 26
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Route of Administration, H1 2014 32
Number of Products by Top 10 Molecule Type, H1 2014 33
Number of Products by Stage and Top 10 Molecule Type, H1 2014 34

Browse more reports on Infectious Diseases Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .

About Us:

RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.